416 related articles for article (PubMed ID: 19009291)
41. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
42. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
[TBL] [Abstract][Full Text] [Related]
43. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
44. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro.
Yates J; Rovis F; Mitchell P; Afzali B; Tsang J; Garin M; Lechler RI; Lombardi G; Garden OA
Int Immunol; 2007 Jun; 19(6):785-99. PubMed ID: 17545278
[TBL] [Abstract][Full Text] [Related]
45. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
Jarnicki AG; Lysaght J; Todryk S; Mills KH
J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
[TBL] [Abstract][Full Text] [Related]
46. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
Ahn JS; Krishnadas DK; Agrawal B
Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
[TBL] [Abstract][Full Text] [Related]
47. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
Vo MC; Nguyen-Pham TN; Lee HJ; Jaya Lakshmi T; Yang S; Jung SH; Kim HJ; Lee JJ
Oncotarget; 2017 Apr; 8(16):27252-27262. PubMed ID: 28460478
[TBL] [Abstract][Full Text] [Related]
48. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
[TBL] [Abstract][Full Text] [Related]
49. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25- regulatory T cells.
Ono M; Shimizu J; Miyachi Y; Sakaguchi S
J Immunol; 2006 Apr; 176(8):4748-56. PubMed ID: 16585568
[TBL] [Abstract][Full Text] [Related]
50. MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.
Hossain DM; Panda AK; Chakrabarty S; Bhattacharjee P; Kajal K; Mohanty S; Sarkar I; Sarkar DK; Kar SK; Sa G
Immunology; 2015 Apr; 144(4):561-73. PubMed ID: 25284464
[TBL] [Abstract][Full Text] [Related]
51. Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta.
Scholzen A; Mittag D; Rogerson SJ; Cooke BM; Plebanski M
PLoS Pathog; 2009 Aug; 5(8):e1000543. PubMed ID: 19680449
[TBL] [Abstract][Full Text] [Related]
52. Removal of regulatory T cell activity reverses hyporesponsiveness and leads to filarial parasite clearance in vivo.
Taylor MD; LeGoff L; Harris A; Malone E; Allen JE; Maizels RM
J Immunol; 2005 Apr; 174(8):4924-33. PubMed ID: 15814720
[TBL] [Abstract][Full Text] [Related]
53. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Scott GB; Carter C; Parrish C; Wood PM; Cook G
Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
[TBL] [Abstract][Full Text] [Related]
54. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.
Moo-Young TA; Larson JW; Belt BA; Tan MC; Hawkins WG; Eberlein TJ; Goedegebuure PS; Linehan DC
J Immunother; 2009 Jan; 32(1):12-21. PubMed ID: 19307989
[TBL] [Abstract][Full Text] [Related]
55. Generation of highly suppressive adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation.
Mahic M; Henjum K; Yaqub S; Bjørnbeth BA; Torgersen KM; Taskén K; Aandahl EM
Eur J Immunol; 2008 Mar; 38(3):640-6. PubMed ID: 18266270
[TBL] [Abstract][Full Text] [Related]
56. ARID2 is a pomalidomide-dependent CRL4
Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
[TBL] [Abstract][Full Text] [Related]
57. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
58. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
59. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells.
Wang B; Li B; Dai Z; Ren S; Bai M; Wang Z; Li Z; Lin S; Wang Z; Huang N; Yang P; Liu M; Min W; Ma H
Int J Biochem Cell Biol; 2014 Oct; 55():98-108. PubMed ID: 25168696
[TBL] [Abstract][Full Text] [Related]
60. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
Hsu AK; Quach H; Tai T; Prince HM; Harrison SJ; Trapani JA; Smyth MJ; Neeson P; Ritchie DS
Blood; 2011 Feb; 117(5):1605-13. PubMed ID: 20978269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
